Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= A [https://en.wikipedia.org/wiki/Single-domain_antibody single domain antibody] directed against the A1 domain of von Willebrand factor (vWF). =Prelimin...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 5: | Line 5: | ||
==[[Thrombotic thrombocytopenic purpura]]== | ==[[Thrombotic thrombocytopenic purpura]]== | ||
| − | # Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. [http://www.nejm.org/doi/full/10.1056/NEJMoa1505533 link to original article] [ | + | # Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. [http://www.nejm.org/doi/full/10.1056/NEJMoa1505533 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26863353 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 03:09, 2 December 2016
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Preliminary data
Thrombotic thrombocytopenic purpura
- Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. link to original article PubMed